Goltsis, Olivia
Bilodeau, Claudia
Wang, Jinxia
Luo, Daochun
Asgari, Meisam
Bozec, Laurent
Pettersson, Ante
Leibel, Sandra L.
Post, Martin http://orcid.org/0000-0003-4258-9303
Funding for this research was provided by:
Canadian Institutes of Health Research (FDN 143309)
Article History
Received: 5 June 2024
Accepted: 21 August 2024
First Online: 2 September 2024
Declarations
:
: This study does not involve animal experiments or human participants. Use of human pluripotent cell lines was approved by the Stem Cell Oversight Committee of The Canadian Institute of Health Research (Patient-specific alveolar type II (ATII) cells from surfactant protein-B deficient induced pluripotent stem cells) in March 2014. The Research Ethical Board of the Hospital for Sick Children confirmed no need for additional ethical approval.
: Not applicable.
: The authors declare that they have no competing interests.
: The authors declare that artificial intelligence is not used in this study.